Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors Leave a Comment / Publication / Joel E Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors Read More »
Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors Leave a Comment / Publication / Joel E Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors Read More »
Pembrolizumab for the treatment of non-small-cell lung cancer Leave a Comment / Publication / Joel E Pembrolizumab for the treatment of non-small-cell lung cancer Read More »
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial Leave a Comment / Publication / Joel E Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial Read More »
Crystal structure of Spot 14, a modulator of fatty acid synthesis Leave a Comment / Publication / Joel E Crystal structure of Spot 14, a modulator of fatty acid synthesis Read More »
Characterization of in vitro and in vivo metabolic pathways of the investigational anticancer agent,2-methoxyestradiol Leave a Comment / Publication / Joel E Characterization of in vitro and in vivo metabolic pathways of the investigational anticancer agent,2-methoxyestradiol Read More »